Vepdegestrant
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications
Correction: A Relative Bioavailability Study of Vepdegestrant Tablets in Healthy Adult Participants.
Correction: A Relative Bioavailability Study of Vepdegestrant Tablets in Healthy Adult Participants.
Journal: European journal of drug metabolism and pharmacokinetics
Published: August 28, 2026
FDA Approval of the First-Ever PROTAC: Vepdegestrant (ARV-471) Marks a New Era in Targeted Protein Degradation.
Journal: Journal of medicinal chemistry
Published: July 23, 2026
Vepdegestrant (Veppanu) for advanced breast cancer.
Journal: The Medical letter on drugs and therapeutics
Published: July 14, 2026
Vepdegestrant for ESR1-mutated breast cancer.
Journal: Trends in pharmacological sciences
Published: June 14, 2026
Vepdegestrant.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: June 09, 2026
From Concept to Clinic: Vepdegestrant (ARV 471) Becomes the First Approved PROTAC Drug.
Journal: Pharmaceutics
Published: May 31, 2026
The PROTAC milestone: FDA approval of vepdegestrant (ARV-471) for ESR1-mutated breast cancer.
Journal: Drug discovery today
Published: May 23, 2026
Clinical Breakthrough in Targeted Protein Degradation: Reflections on the Approval of ARV-471.
Journal: Cancer innovation
Published: May 18, 2026
Harnessing p53 for Proximity Killing.
Journal: International journal of molecular sciences
Published: May 18, 2026
Approval of First PROTAC Opens New Era for Targeted Protein Degradation.
Journal: Cancer discovery
Published: May 15, 2026
Last Updated: 09/26/2026